1 Belmaker, R.H. & Agam, G. Major depressive disorder. N. Engl. J. Med. 358, 55–68 (2008).

2 Howren, M.B., Lamkin, D.M. & Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71, 171–186 (2009).

3 Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446–457 (2010).

4 Krishnan, V. & Nestler, E.J. The molecular neurobiology of depression. Nature 455, 894–902 (2008).

5 Brink, C.B., Harvey, B.H. & Brand, L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent Pat. CNS Drug Discov. 1, 29–41 (2006).

6 Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805–809 (2003).

7 Koo, J.W. & Duman, R.S. IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. USA 105, 751–756 (2008).

8 David, D.J. et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62, 479–493 (2009).

9 Warner-Schmidt, J.L. & Duman, R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16, 239–249 (2006).

10 Gulbins, E. & Kolesnick, R. Raft ceramide in molecular medicine. Oncogene 22, 7070–7077 (2003).

11 Grassmé, H. et al. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276, 20589–20596 (2001).

12 Perrotta, C. et al. Syntaxin 4 is required for acid sphingomyelinase activity and apoptotic function. J. Biol. Chem. 285, 40240–40251 (2010).

13 Grassmé, H. et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 9, 322–330 (2003).

14 Baumann, P. et al. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin. Neurosci. 7, 231–247 (2005).

15 Kölzer, M., Werth, N. & Sandhoff, K. Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett. 559, 96–98 (2004).

16 Kornhuber, J. et al. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J. Med. Chem. 51, 219–237 (2008).

17 Ranganathan, R., Sawin, E.R., Trent, C. & Horvitz, H.R. Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine. J. Neurosci. 21, 5871–5884 (2001).

18 Dempsey, C.M., Mackenzie, S.M., Gargus, A., Blanco, G. & Sze, J.Y. Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate Caenorhabditis elegans egg-laying behavior. Genetics 169, 1425–1436 (2005).

19 De Stefanis, D. et al. Increase in ceramide level alters the lysosomal targeting of cathepsin D prior to onset of apoptosis in HT-29 colon cancer cells. Biol. Chem. 383, 989–999 (2002).

20 Hisaki, H. et al. In vivo influence of ceramide accumulation induced by treatment with a glucosylceramide synthase inhibitor on ischemic neuronal cell death. Brain Res. 1018, 73–77 (2004).

21 Peltier, J., O'Neill, A. & Schaffer, D.V. PI3K and CREB regulate adult neural hippocampal progenitor proliferation and differentiation. Dev. Neurobiol. 67, 1348–1361 (2007).

22 Zhang, Y., Li, X., Carpinteiro, A. & Gulbins, E. Acid sphingomyelinase amplifies redox signaling in Pseudomonas aeruginosa–induced macrophage apoptosis. J. Immunol. 181, 4247–4254 (2008).

23 Mathias, S. et al. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 β. Science 259, 519–522 (1993).

24 Wiegmann, K., Schütze, S., Machleidt, T., Witte, D. & Krönke, M. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 78, 1005–1015 (1994).

25 Kim, M.Y., Linardic, C., Obeid, L. & Hannun, Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor α and γ-interferon. Specific role in cell differentiation. J. Biol. Chem. 266, 484–489 (1991).

26 Brenner, B. et al. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J. Biol. Chem. 272, 22173–22181 (1997).

27 Lepple-Wienhues, A. et al. Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids. Proc. Natl. Acad. Sci. USA 96, 13795–13800 (1999).

28 Müller, N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr. Opin. Investig. Drugs 11, 31–42 (2010).

29 Walker, J.R. et al. Psychiatric disorders in patients with immune-mediated inflammatory diseases: prevalence, association with disease activity, and overall patient well-being. J. Rheumatol. Suppl. 88, 31–35 (2011).

30 Rudisch, B. & Nemeroff, C.B. Epidemiology of comorbid coronary artery disease and depression. Biol. Psychiatry 54, 227–240 (2003).

31 Kojima, M. et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum. 61, 1018–1024 (2009).

32 Tabas, I. Sphingolipids and atherosclerosis: a mechanistic connection? A therapeutic opportunity? Circulation 110, 3400–3401 (2004).

33 Kornhuber, J. et al. High activity of acid sphingomyelinase in major depression. J. Neural Transm. 112, 1583–1590 (2005).

34 Horinouchi, K. et al. Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat. Genet. 10, 288–293 (1995).

35 Lozano, J. et al. Niemann-Pick disease versus acid sphingomyelinase deficiency. Cell Death Differ. 8, 100–103 (2001).

36 Lakso, M. et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl. Acad. Sci. USA 93, 5860–5865 (1996).

37 Amato, D., Müller, C.P. & Badiani, A. Increased drinking after intra-striatal injection of the dopamine D2/D3 receptor agonist quinpirole in the rat. Psychopharmacology (Berl.) 223, 457–463 (2012).